Core Viewpoint - Guangyuyuan (600771) emphasizes its commitment to investor communication and the continuous improvement of its operational quality, aiming for double-digit growth in key performance indicators by 2025 [1] Group 1: Investor Communication - The company actively monitors various investor communication platforms and values objective feedback from investors, which is analyzed and reported to management [1] - Historical performance is acknowledged, but the company focuses on current and future operations without complacency [1] Group 2: Operational Performance - The company projects double-digit growth in its three periodic reports for 2025, with significant improvements in cash flow, accounts receivable, and sales expense ratio [1] - Evidence of operational success includes enhanced brand collaboration, top-tier chain partnerships, and the first national approval for Banxia Xiexin Decoction granules [1] Group 3: Future Strategy - For 2026, the company will prioritize "growth" as a value anchor and adopt a proactive mindset to achieve results, ensuring sustainable and high-quality development [1]

Group 1 - The company Guangyuyuan announced that its eighth board of directors will expire on January 17, 2026, and the board's election work is currently in preparation [2] - The board's term extension aims to ensure continuity and stability in the company's operations, with all specialized committees and senior management's terms being extended accordingly [2] - The current independent director, Zhao Xuanmin, has served since January 15, 2020, and will reach the six-year limit for continuous service before the board's election is completed [2]

Core Viewpoint - The company is actively monitoring sales dynamics of similar products in the industry and analyzing successful brands' marketing strategies to enhance its own competitiveness [1] Group 1: Company Strategy - The company has a diverse range of alcoholic products with historical brand value and notable quality advantages [1] - The company acknowledges its current disadvantages in product channel coverage, brand market competitiveness, and purchasing scenarios [1] - A new operational plan has been developed to launch different specifications like "Youth Small Cannon and Family Gift Box" to cater to various consumer needs and usage scenarios [1] Group 2: Marketing and Expansion Efforts - The company is focusing on regional pilot projects based in Shanxi to expand nationwide through various channels [1] - Marketing efforts include online and offline strategies such as exposure on China Railway 12306, public accounts, video accounts, and offline pop-up events [1] - The alcoholic beverage business currently represents a small proportion of the company's overall revenue, and investors are advised to view this with rationality [1]

证券代码：600771 证券简称：广誉远 编号：临 2026-001 关于董事会延期换届及部分独立董事任期届满的提示性 公告 特别提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会延期换届的情况 广誉远中药股份有限公司（以下简称"公司"）第八届董事会将于 2026 年 1 月 17 日届满。目前，公司董事会换届选举工作尚在筹备中，公司董事会将延期换届。为保证 董事会相关工作的连续性和稳定性，公司董事会各专门委员会、高级管理人员的任期将 相应顺延。 在公司董事会换届选举工作完成前，公司第八届董事会全体成员、董事会各专门委 员会成员及高级管理人员将按照相关法律法规及《公司章程》等规定，继续履行董事及 高级管理人员的职责和义务。 二、部分独立董事连续任职时间达到六年的情况 根据《上市公司独立董事管理办法》及公司《独立董事制度》等相关规定，独立董 事在公司连续任职时间不得超过六年。公司现任独立董事赵选民自 2020 年 1 月 15 日起 担任公司独立董事，在公司连续任职时间达到六年，将届满离任。由于公司董事会换届 选举 ...

Core Viewpoint - Guangyuyuan (600771) emphasizes its commitment to quality and traditional pharmaceutical practices, ensuring the efficacy of its classic products like Gui Ling Ji and Ding Kun Dan, while maintaining strict adherence to GMP standards in production [1] Group 1: Quality Control - The company views product quality as its core lifeline, implementing a comprehensive quality control system throughout the entire process from raw material procurement to finished product release [1] - Guangyuyuan's commitment to high standards in quality management is reflected in its adherence to traditional pharmaceutical teachings, ensuring that every batch of products is stable and reliable [1] Group 2: Strategic Focus - The company will continue to focus on its "1541" strategic framework, centering on its main responsibilities and core growth objectives, with an emphasis on performance-driven management and sales breakthroughs [1] - Guangyuyuan aims to enhance operational quality while safeguarding consumer rights through its commitment to high-quality product manufacturing [1]

Core Viewpoint - Guangyuyuan (600771) has reported significant achievements in its operational goals for 2025, laying a solid foundation for its 2026 objectives, with a focus on systematic layout, mechanism improvement, channel expansion, operational quality enhancement, and brand building [1] Group 1: Operational Performance - In the first, second, and third quarters of 2025, the company achieved double-digit growth in core indicators [1] - The company became the first in the nation to receive approval for the ancient classic prescription new drug Banxia Xiexin Decoction granules [1] Group 2: Brand Development - The brand's visibility has been enhanced through participation in various media programs, including CCTV's "Health China Says" and "Health China Travels the World," as well as special features like "Time Slows Down with Qihuang" [1] Group 3: Strategic Focus - The company acknowledges the gap between current operational results and market expectations, committing to focus on value growth, core responsibilities, standardized operations, and governance improvement to promote sustainable and healthy development [1]

Core Viewpoint - Guangyuyuan (600771) stated that its production and operations are normal, with all tasks being carried out in an orderly manner by professional personnel, and the company will fulfill its information disclosure obligations for any matters that need to be disclosed [1] Group 1 - The company confirmed that its production and operations are functioning normally [1] - All tasks are being advanced in an orderly manner with the involvement of professional personnel [1] - The company emphasized its commitment to timely information disclosure for any relevant matters [1]

Group 1 - The company, Guangyuyuan (600771), has stated that it has timely, accurately, and completely disclosed relevant information through regular reports and temporary announcements [1] - The company emphasizes that its operations are compliant and that it is focused on the core goal of "growth," with continuous improvement in operational quality [1]

Core Viewpoint - Guangyuyuan (600771) has introduced various specifications of its proprietary medicine, Gui Ling Ji, based on factors such as efficacy, treatment duration, consumption scenarios, and market demand [1] Product Specifications - The company offers Gui Ling Ji in multiple specifications: 12 capsules, 18 capsules, 24 capsules, 30 capsules, 36 capsules, and 60 capsules [1] - Consumers are encouraged to purchase and use the product according to their needs under the guidance of a physician [1]

Core Viewpoint - Guangyuyuan (600771) emphasizes its commitment to maintaining open communication with investors and continuously improving its operations based on feedback received from various capital market channels [1] Group 1 - The company actively engages with investors through various channels to gather their opinions and suggestions [1] - Guangyuyuan adopts a transparent and open attitude towards investor communications [1] - The company aims to optimize and improve its operations by considering the actual circumstances of the company alongside investor feedback [1]